China–India pharmaceutical industry cooperation in the context of “One Belt,One Road”: Opportunities,challenges,and the way forward

Abstract

To promote the “Belt and Road Initiative” (BRI) in India, it is necessary to highlight the economic attributes, highlight the role of the market, cultivate new growth points of cooperation, and consolidate the foundation of common interests. Industrial cooperation is an important part not only of the “Belt and Road” construction, but also of economic cooperation between the countries. The pharmaceutical product industry is India's most advantageous industry, and it is also an industry with which India hopes to strengthen cooperation with China. In the context of “One Belt, One Road,” China–India pharmaceutical industry cooperation faces both rare opportunities and some challenges, but from the perspective of development trends, obstacles are gradually reducing. Promoting Sino–Indian pharmaceutical industry cooperation requires the joint efforts of government departments, industry chambers of commerce, and pharmaceutical companies. The key is to choose the right cooperation field and path. Strengthening China–India pharmaceutical industry cooperation is conducive to fostering new growth points for China–India economic cooperation, reducing India's concerns about the BRI, and promoting the BRI in India and the entire South Asian region.

Keywords

cooperation generic drugs Indian pharmaceutical industry One Belt One Road

Get full access to this article

View all access options for this article.

References

Department of Pharmaceuticals (2016–2017) Ministry of Chemicals and Fertilizers: Annual report 2016–2017. Available at: http://pharmaceuticals.gov.in/sites/default/files/Chemical%20Pharma%20－2016－17%20English%20Final%20%20for%20mail%20%282%29.Pdf (accessed xxxx).

Pharmaceuticals Export Promotion Council of India (2017) Annual report，2016－2017.

Chaudhuri

(2013) The pharmaceutical industry in India after TRIP. In: Fgren

Williams

(eds) The New Political Economy of Pharmaceuticals. London: Palgrave Macmillan.

Chen

(2006) The reason and enlightenment of the rise of Indian pharmaceutical industry: Yunnan Social Sciences 05(16).

Chen

(2012) India’s patent laws protection and enlightenment for its pharmaceutical industry: Jiangsu Science and Technology Information 14 (11).

Economic Times (2015) Modi’s visit to China to reduce trade deficit, hope China buys more Indian medicines.

Jia

(2018) Policy dividends along the Belt and Road. Medical Economic News 5(11).

Khan

Nasim

(2016) Impact of product patent regime on pharmaceutical companies in India. In: Sushil

Burgess

(eds) Flexible Work Organizations: The Challenges of Capacity Building in Asia. New Delhi: Springer India.

(2016) Analysis of institutional factors in the development of generic drugs in India and its reference to my country. Science and Technology Progress and Countermeasures 7(13).

10.

(2012) India’s pharmaceutical patent strategy and its enlightenment to my country. China Pharmaceutical Affairs 13(5).

11.

Liu

(2016) The global generic drug market will reach approximately US$314.9 billion in 2016. China Industry Information Network 4(24): 16–20.

12.

Liu

(2016) Who can share the 500 billion generic drug market. Beijing Business Daily , 23 August.

13.

(2017) Comparative analysis of Chinese and Indian patent systems in the pharmaceutical industry. Southeast Asia and South Asia Studies 6(2).

14.

Malhotra

(2010) Impact of TRPS in India. London: Palgrave Macmillan.

15.

Malhotra

(2016) Impact of TRIPS in India, drug registration threshold raised again, generic drugs usher in a knockout. Daily Economic News , 28 December. Available at: http://www.nbd.com.cn/articles/2015-12-28/973524.Html (accessed xxxx).

16.

Park

(2019) Traditional and complementary medicine for promoting healthy ageing in WHO Western Pacific Region: Policy implications from utilization patterns and current evidence. Integrative Medicine Research 10(1): 100469.

17.

Qian

(2013) Inspiration from the internationalization experience of Indian pharmaceutical industry to Chinese pharmaceutical enterprises. Shanghai Pharmaceuticals 13(24).

18.

Rahim

(2014) Emergence of biopharmaceutical innovators in China, India: Brazil and South Africa as global competitors and collaborators. 4(28) 29–36.

19.

Sang

(2014) US$259 billion drugs face patent expiration in the next seven years. China Net 2(14): 45–56.

20.

Sharma

(2019) India’s approach to China’s Belt and Road Initiative—Opportunities and concerns. The Chinese Journal of Global Governance 13(45).

21.

Sun

(2017) Can Tezhixing return to the Chinese market can reverse Hisun’s development trend? China Business Network, 22 July. Available at: http://www.cb.com.cn/yiyao/2017_0722/1191963 (accessed xxxx).

22.

Wang

(2017) Seminar on drug quality management in developing countries held. China Daily 12(22): 44–56. Available at: http://en.chinadaily.com.en/2017-07/12/content_30090848.Html

23.

Wang

(2018) Seminar on drug quality management in developing countries held. China Daily 11(8).

24.

World Trade Organization (2001) Declaration on the TRIPS agreement and public health: Doha, Nov. 9(14) 01–02. Available at: https://www.wto.org/english/thewto_e/minist_e/min01_e/mindecl_trips_e.pdf (accessed xxxx).

25.

Zhao

(2014) Indian patent law prevents evergreening of pharmaceutical patents and harms incremental innovation. China Pharmaceutical Affairs 18(12).

26.

Zheng

(2010) India’s chemical industry development from the perspective of global value chain: The enlightenment of the development model to my country. Chinese Journal of New Drugs 2(8).

27.

Zhong

(2007) Influence of the implementation of India’s new patent law on pharmaceutical enterprises. Shanghai Pharmaceuticals 3(4).

28.

Zhu

(2015) Analysis of import and export situation of APIs in my country in 2014. Fine and Specialty Chemicals 13(6).